<1%, postmarketing, and/or case reports: Abnormal hepatic function tests, acneiform eruption, acute hepatic failure, agitation, agranulocytosis, akathisia, alopecia, amenorrhea, anaphylaxis, anemia, blurred vision, bronchopneumonia, bronchospasm, cardiac arrhythmia, cholestasis, cogwheel rigidity, confusion, decreased libido, depression, dizziness, dyskinesia, dysmenorrhea, dyspnea, edema, erectile dysfunction, exfoliative dermatitis, extrasystoles, facial edema, galactorrhea, gynecomastia, heatstroke, hepatic insufficiency, hepatitis, hyperammonemia, hyperhidrosis, hyperprolactinemia, hyperpyrexia, hypersensitivity angiitis, hypersensitivity reaction, hypertension, hyperthermia, hypoglycemia, hypokinesia, hypotension, hypothermia, injection site reaction, insomnia, jaundice, laryngeal edema, laryngospasm, leukocytosis, leukopenia, lymphocytosis with monocytosis, maculopapular rash, mask-like face, mastalgia, menorrhagia, motor dysfunction, muscle rigidity, muscle twitching, nausea, neonatal withdrawal, neuroleptic malignant syndrome, neutropenia, nystagmus, opisthotonus, orthostatic hypotension, pancytopenia, priapism, prolonged Q-T interval on ECG, pruritus, restlessness, rhabdomyolysis, sedation, seizure, SIADH, skin photosensitivity, skin rash, tachycardia, tardive dyskinesia, tardive dystonia, thrombocytopenia, torsades de pointes, torticollis, trismus, urinary retention, urticaria, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, vomiting, weight gain, weight loss
Decanoic acid acts as a non-competitive AMPA receptor antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects.  This direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anticonvulsant effect of the MCT ketogenic diet .  Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic. 
The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).